Visit KQAK 105.7
Visit The Peak 104.1
Visit 95.7 The Ranch
Visit 92.5 The Ticket
Visit KBNW 104.5AM AND 1340AM
Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Creative Medical Technology Holdings, Inc. - Common Stock (NQ:CELZ)

0.9500 +0.0100 (+1.06%)
Delayed Quote Updated: 12:28 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Creative Medical Technology Holdings, Inc. - Common Stock

News headline image
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Creative Medical Technology Holdings Provides Corporate Update
From Creative Medical Technology Holdings, Inc.
Via Business Wire
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
Via AB Newswire
News headline image
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
Via ACCESSWIRE
News headline image
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Via ACCESSWIRE
News headline image
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
Via ACCESSWIRE
News headline image
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
From Creative Medical Technology Holdings, Inc.
Via Business Wire
InvestorNewsBreaks – Creative Medical Technology (NASDAQ: CELZ) Expects $17 Million Gross Proceeds from Private Placement
Via Investor Brand Network
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.